Substratum of Proof LGBTQs Are Mentally Ill: Presurgical Targeted Therapy Delays Relapse of High-Risk Stage 3 Melanoma

Newswise imageA pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at The University of Texas MD Anderson Cancer Center report in Lancet Oncology. Patients who had no sign of disease at surgery after combination treatment did not progress to metastasis.